Whole-cell and acellular pertussis vaccines.
OBJECTIVE
To provide a review of pertussis vaccines, including information on efficacy, adverse reactions, and antibody production following administration of both whole-cell and acellular pertussis vaccines.


METHODS
A MEDLINE search and extensive review of journals was conducted to identify the information for this review.


METHODS
Pertinent studies reporting experience with pertussis vaccinations were reviewed.


RESULTS
The differences in efficacy, adverse reactions, and antibody responses between whole-cell and acellular pertussis vaccines are emphasized. The status of acellular pertussis vaccination in the US is defined.


CONCLUSIONS
Acellular (chemically detoxified or recombinant) pertussis vaccine formulation appears to cause fewer adverse reactions than whole-cell vaccine in most studies. Clinical efficacy and safety in the very young has not been well established. Thus, acellular pertussis vaccine is reserved for the 4th and 5th doses in the US. Oral or intranasal formulations of the pertussis vaccine are being evaluated.
Wintermeyer
S M
SM
Ohio State University, Columbus.
Nahata
M C
MC
Kyllonen
K S
KS
D000907:Antibodies, Bacterial / Q000276:immunology / Q000302:isolation & purification; D001886:Bordetella pertussis / Q000276:immunology / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007223:Infant; D007231:Infant, Newborn; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology; D014611:Vaccination; D010566:Virulence Factors, Bordetella / Q000009:adverse effects; D014917:Whooping Cough / Q000276:immunology / Q000517:prevention & control
D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella